(redirected from Zioptan)


(ta-floo-prost) ,


(trade name)


Therapeutic: ocular hypotensive agent
Pharmacologic: prostaglandins
Pregnancy Category: C


Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.


Acts as a prostaglandin analogues that decreases intraocular pressure by ↑ uveoscleral outflow.

Therapeutic effects

↓ intraocular pressure.


Absorption: Absorbed through cornea and is converted to the active metabolite tafluprost acid.
Distribution: Unknown.
Metabolism and Excretion: Further metabolized and eliminated.
Half-life: Unknown.

Time/action profile (↓ in intraocular pressure)

Ophthwithin 2–4 hr12 hr24 hr


Contraindicated in: Pediatric: Avoid use in children due to unknown safety of chronic ↑ pigmentation.
Use Cautiously in: Aphakia, pseudoaphakia with a torn posterior lens capsule; Known risk factors for macular edema; Obstetric: Women with child-bearing potential should practice adequate contraception; Lactation: Use cautiously in nursing women.

Adverse Reactions/Side Effects

Ear, Eye, Nose, Throat

  • conjunctival hyperemia (most frequent)
  • blurred vision
  • cataract
  • permanent iris pigmentation
  • eyelid pigmentation
  • lash pigmentation/increased thickness/↑ number
  • macular edema
  • ocular stinging/irritation


Drug-Drug interaction

Note noted.


Ophthalmic (Adults) One drop once daily (into conjunctival sac) in the evening into affected eye(s).


Ophthalmic solution : 0.0015% in 0.3 mL single-use containers

Nursing implications

Nursing assessment

  • Measure intraocular pressure periodically during therapy.

Potential Nursing Diagnoses

Readiness for enhanced knowledge, related to medication regimen (Patient/Family Teaching)


  • Ophthalmic: Wash hands prior to instillation. Pull lower lid downward and look up. Instill 1 drop in conjunctival sac each evening. Each unit is for one-time use; discard after using. Store unopened foil pouches in refrigerator. Do not open pouch until ready to use.
    • If used with other ophthalmic medications, administer at least 5 min apart.

Patient/Family Teaching

  • Instruct patient to use drops as directed. Do not use more than 1 drop daily; may increase intraocular pressure. Do not use for a condition for which it was not prescribed. Do not share with others, even if they have the same symptoms; may cause harm.
  • Advise patient to read the Patient Information Leaflet prior to initiating therapy and with each Rx refill in case of changes.
  • Inform patient of potential side effects including brownish color of the iris; may be permanent. Also, darkening of the eyelid, increasing length, thickness, color, or number of eyelashes, and hair growth on eyelids; usually reversible.
  • Advise patient to notify health care professional if eye injury, eye infection, sudden loss of vision, eye surgery, swelling and redness around eye, or problems with eyelids occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient use adequate contraception during therapy and to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

Evaluation/Desired Outcomes

  • Reduction of intraocular pressure.
References in periodicals archive ?
at Request Letter 2013-5788; see also MERCK, PATIENT INFORMATION: ZIOPTAN 5, https://www.
These include glaucoma treatment pill Zioptan, hepatitis C drug Victrelis, and an extended version of its combination type-2 diabetes pill, Janumet XR.
Merck on Tuesday announced that the FDA has approved it's eye solution Zioptan for the treatment of a common eye condition.
Zioptan (tafluprost ophthalmic solution) is now able to be used in the US for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Approval of this drug was based on two Phase III clinical trials which showed that Zioptan once-daily lowered intraocular pressure at three and six months.
Zioptan is expected to be available for patients next month and will be priced at USD97 for a 30-day supply.
Received FDA approval for ZIOPTAN (tafluprost ophthalmic solution) 0.
ZIOPTAN (pronounced zye-OP-tan) is approved for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension.
The approval of ZIOPTAN will provide a new, effective option to lower IOP," said George L.
The FDA approval of ZIOPTAN was based on efficacy and safety results from five controlled clinical studies of up to two years in 905 patients.
In clinical studies of up to two years in duration, ZIOPTAN, dosed once-daily in the evening lowered IOP at 3 and 6 months by 6-8 mmHg and 5-8 mmHg respectively, from a baseline pressure of 23-26 mmHg (mmHg = millimeters of mercury, a measurement of fluid pressure in the eye).
Merck anticipates that ZIOPTAN will be available to customers in March.